Our NME's contain molecular conjugates designed to join two separate bioactives into a single NME. In systemic circulation, the molecular conjugates are designed to be cleaved by specific enzymes in order to release the two bioactives. By releasing the bioactive components of the conjugate molecule allows the bioactives to reach their targets more efficiently and have greater efficacy than if the bioactives were dosed independently or in combination.The new molecular entities ("NMEs") dissociate completely in the GI tract to deliver high plasma and tissue levels of active molecule in the free individual bioactive form.

Download Brochure

VCB-101: Novel conjugate of monomethyl fumarate (MMF)

  • A Novel Ester Conjugate of MMF and EPA for the treatment of Multiple Sclerosis and Psoriasis
  • Designed for slow and sustained release of the actives
  • Targeted to reduce GI side-effect profile and also Dose Dependent Flushing of DimethylFumarate
  • Pre-Clinical: Completion and Currently at IND filing stage
  • Regulatory: 505(b)(2) Pathway
  • Intellectual Property: Issued US Patent. National Stage Filings were filed in 12 countries with their respective PTO’s
VCB-101 Indications:
  • Relapsing Remitting Multiple Sclerosis (RRMS)
  • Psoriasis

Mechanism: VCB-101 is

  • prodrug of monomethyl fumarate (MMF) that activates a transcription factor called the nuclear factor (erythroid-derived 2)-like 2, also known as NFE2L2 or Nrf2

 

VCB-102: Novel conjugate of monomethyl fumarate (MMF)

  • A Novel Conjugate of MMF for the treatment Psoriasis
  • Designed for slow and sustained release of the actives
  • Targeted to reduce GI side-effect profile and also Dose Dependent Flushing of DimethylFumarate
  • Intellectual Property: Issued US Patent. National Stage Filings were filed.
VCB-102 Indications:
  • Psoriasis

Mechanism: VCB-102 is

  • prodrug of monomethyl fumarate (MMF) that activates a transcription factor called the nuclear factor (erythroid-derived 2)-like 2, also known as NFE2L2 or Nrf2

 

VCB-201: Novel conjugate of halofenate

  • A Novel Next Generation Halofenate Derivative for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
  • Expected to be more efficacious than the arhalofenate which is currently in Phase III clinical trials
  • Synergistic pharmacological effect from omega-3 Fatty acids as an anti-inflammatory agent as a comorbidity in gout is an auxiliary benefit
  • Designed for slow and sustained release of the actives in the small intestine
  • Regulatory: Targeting 505(b)(1) Pathway
  • Intellectual Property: Issued US Patent. National Stage Filings were filed in 12 countries with their respective PTO’s
VCB-201 Indications:
  • Gout
  • Hypertriglyceridemia
  • Uricosuria
  • Hepatic encephalopathy

Mechanism: VCB-201 is

  • prodrug of arhalofenate which upon absorption is converted to its active form, halofenic acid
  • halofenic acid blocks the monosodium urate crystal-stimulated production of IL-1β by macrophages and block renal uric acid transporter URAT1, thereby reduces inflammation and uricosuria

 

VCB-301: Novel conjugate of miglitol

  • A Novel Ester Conjugate of Miglitol and EPA for the treatment of Type 2 diabetes
  • Designed for slow and sustained release of the actives
  • Targeted to reduce GI side-effect profile
  • Regulatory: 505(b)(2) Pathway
  • Intellectual Property: Issued US Patent
VCB-301 Indications:
  • Type 2 diabetes
  • Diabetes with constipation

Mechanism: VCB-301 is

  • prodrug of miglitol which upon absorption releases miglitol
  • miglitol is an α-glucosidase inhibitor. It works by slowing down the digestion of carbohydrates into glucose. This results in a smaller rise in blood sugar levels following a meal.